
    
      The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once
      daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american
      college of rheumatology (ACR) 20 response at Week 16 (Part A).
    
  